
Liquidia Corp
100
Recent developments include Liquidia gearing up for Q3 earnings reporting, settling litigation disputes with United Therapeutics Corporation for $380.7 million with label limitations on YUTREPIA, and ongoing market and economic pressures affecting the broader sector.
- Liquidia prepared to report Q3 earnings with market anticipation of performance updates [N4].
- The company settled disputes with United Therapeutics Corporation for $380.7 million, agreeing to limit the YUTREPIA label as part of the settlement [N7].
- Market conditions showed stocks sharply lower due to inflation concerns and sector-specific pressures, impacting sentiment [N5].
- Stocks and bonds declined following a strong CPI report, reflecting macroeconomic influences [N6].
- Stocks retreated amid persistent U.S. price pressures, affecting investor confidence [N8].
Liquidia Corp operates in the biopharmaceutical sector focusing on respiratory and vascular diseases, notably pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company markets YUTREPIA, an inhaled dry powder formulation of treprostinil approved by the FDA in May 2025, and shares profits from generic treprostinil injection sales through a promotion agreement with Sandoz. Liquidia employs a targeted commercial field force in the U.S. and is developing additional product candidates including L606, a liposomal treprostinil formulation in clinical trials. The company has incurred significant operating losses historically and maintains liquidity sufficient to fund operations beyond one year from the latest financial statements. It has also settled litigation with United Therapeutics Corporation, impacting product labeling and financial obligations.
Liquidia Corp is a biopharmaceutical company specializing in treatments for pulmonary arterial hypertension and related diseases. It generates revenue primarily from its FDA-approved inhaled treprostinil product YUTREPIA and a profit-sharing promotion agreement with Sandoz for generic treprostinil injection. The company is advancing clinical development of additional formulations and indications. As of September 30, 2026, Liquidia reported a net loss of $236.3 million and held $396 million in cash and equivalents, with liquidity ratios indicating near parity of current assets to liabilities. The company recently settled significant litigation with United Therapeutics Corporation. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Liquidia’s proprietary PRINT technology and FDA-approved inhaled treprostinil product provide a differentiated therapeutic option for PAH and PH-ILD patients. The company’s exclusive promotion agreement with Sandoz for generic treprostinil injection adds a revenue stream. Clinical development of L606 and planned studies for additional indications could expand the product portfolio and market reach. The recent settlement of litigation with United Therapeutics removes legal uncertainties, potentially enabling more focused commercialization efforts.
Liquidia faces significant operating losses and uncertainty regarding sustained revenue generation from YUTREPIA and other product candidates. Constraints on generic treprostinil injection sales due to limited infusion pump availability may restrict revenue growth. The company’s reliance on FDA approvals and regulatory compliance introduces risks. Litigation settlements impose financial obligations and product label limitations. Market competition and reimbursement challenges could impact commercial success.
Liquidia’s moat is supported by its proprietary PRINT particle engineering technology enabling differentiated inhaled drug delivery, FDA approval of YUTREPIA for PAH and PH-ILD, and exclusive commercial rights to generic treprostinil injection through a promotion agreement with Sandoz. The company’s targeted commercial infrastructure and ongoing clinical development pipeline further contribute to its competitive positioning. However, the biopharmaceutical industry’s inherent regulatory, clinical, and competitive risks remain significant.
• Regulatory and Approval Risks: The company’s ability to maintain FDA approval for YUTREPIA and obtain approvals for other product candidates is uncertain and critical to revenue generation.
• Commercialization and Market Risks: Constraints on infusion pump availability limit patient access to generic treprostinil injection, impacting sales. Market acceptance and reimbursement challenges may affect product uptake.
• Financial and Liquidity Risks: Significant operating losses and accumulated deficits pose risks to financial stability. The company’s liquidity depends on successful commercialization and capital management.
• Litigation and Legal Risks: Settlements with United Therapeutics impose financial costs and product label restrictions, which may affect market potential and operational flexibility.
• Cybersecurity Risks: Information technology failures, security breaches, or data loss could disrupt operations and harm the company’s reputation and financial condition.
Business trends: Expansion of commercial sales of YUTREPIA and promotion agreement revenues, ongoing clinical development of L606 and new indications.
Execution milestones: Completion of pivotal clinical trials, maintenance of FDA approvals, and successful commercialization efforts.
Key risks: Regulatory approval uncertainties, commercialization constraints due to infusion pump availability, financial losses, and litigation-related product label limitations.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Liquidia Corp is a biopharmaceutical company focused on respiratory and vascular diseases such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- The company operates through wholly owned subsidiaries Liquidia Technologies, Inc. and Liquidia PAH, LLC.
- Liquidia generates revenue from sales of YUTREPIA (treprostinil) inhalation powder, approved by the FDA in May 2025 for PAH and PH-ILD, with commercialization starting June 2025.
- The company has a promotion agreement with Sandoz Inc. to share profits from sales of generic treprostinil injection in the U.S., with Liquidia having exclusive commercial rights for this product.
- YUTREPIA uses proprietary PRINT technology for precise particle engineering to improve delivery and dosing convenience.
- Liquidia is developing L606, a liposomal formulation of treprostinil administered via a next-generation nebulizer, currently in clinical trials including a pivotal study for PH-ILD.
- The company plans clinical studies for YUTREPIA in additional indications including PH-COPD, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and Raynaud’s phenomenon associated with systemic sclerosis.
- Liquidia has incurred significant operating losses historically, with net losses of $68.9 million in 2025 and an accumulated deficit of $626.3 million as of December 31, 2025.
- As of September 30, 2026, Liquidia had cash and cash equivalents of approximately $396 million and current assets of about $597 million against current liabilities of about $585 million, resulting in a current ratio of 1.02 and a cash ratio of 0.68.
- The company’s net loss for the quarter ended September 30, 2026 was $236.3 million, with basic and diluted EPS of -$2.64 per share.
- Liquidia’s commercial field force targets healthcare providers and stakeholders involved in PAH and PH-ILD treatment and reimbursement in the U.S.
- The company’s cost of product sales includes third-party manufacturing, packaging, freight, storage, overhead, and royalties, with expectations of increasing cost of product sales percentage as inventory costs normalize.
- Service revenue is derived from the promotion agreement with Sandoz, including costs related to commercial field force and amortization of intangible assets.
- Liquidia faces constraints on Treprostinil Injection sales due to limited availability of the CADD-MS 3 infusion pump, which is no longer manufactured or supported, limiting patient access.
- The company has settled litigation disputes with United Therapeutics Corporation for $380.7 million and agreed to limit the YUTREPIA label as part of the settlement.
- Liquidia’s corporate headquarters and primary facilities are located in Morrisville, North Carolina, with leases extending through 2031 and 2036 for additional space.
- The company’s board and management have established cybersecurity risk management frameworks with oversight by the Audit Committee and regular reporting on cybersecurity risks and incidents.
- Liquidia has not paid cash dividends and does not anticipate paying dividends in the foreseeable future due to operational and contractual constraints.
- The company’s future funding needs depend on maintaining FDA approval and commercializing YUTREPIA and advancing clinical development of product candidates.
- Liquidity ratios and financial figures are derived from the latest SEC filings as of September 30, 2026, and are provided for informational purposes only.
Generated 2026-11-10
- S1 | 2026-03-05 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates | https://www.nasdaq.com/articles/zymeworks-inc-zyme-misses-q3-earnings-estimates
- N2 | 2026-11-05 | www.nasdaq.com | Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/protagonist-therapeutics-ptgx-q3-earnings-and-revenues-surpass-estimates
- N3 | 2026-10-29 | www.nasdaq.com | Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/stoke-therapeutics-inc-stok-reports-q3-loss-tops-revenue-estimates
- N4 | 2026-10-28 | www.nasdaq.com | Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect? | https://www.nasdaq.com/articles/liquidia-gears-report-q3-earnings-what-can-investors-expect
- N5 | 2026-10-15 | www.nasdaq.com | Stocks Sharply Lower on Inflation Woes and Slumping Chipmakers | https://www.nasdaq.com/articles/stocks-sharply-lower-inflation-woes-and-slumping-chipmakers
- N6 | 2026-10-14 | www.nasdaq.com | Stocks and Bonds Fall on a Strong CPI Report | https://www.nasdaq.com/articles/stocks-and-bonds-fall-strong-cpi-report
- N7 | 2026-10-14 | www.nasdaq.com | LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label | https://www.nasdaq.com/articles/lqda-settles-uthr-disputes-3807m-limits-yutrepia-label
- N8 | 2026-10-14 | www.nasdaq.com | Stocks Retreat on Sticky US Price Pressures | https://www.nasdaq.com/articles/stocks-retreat-sticky-us-price-pressures
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


